The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | DLBCL highlights from ASH 2024
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, highlights the key updates from ASH 2024 in diffuse large B-cell lymphoma (DLBCL). He mentions promising results of combinations with R-CHOP, noting that these combinations are now being tested in Phase III trials. Dr Shah also speaks about the continued efficacy of polatuzumab at the five-year follow-up of the POLARIX trial (NCT03274492). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Yeah, so lots of interesting data has come out in diffuse large B-cell lymphoma. I would say a session that sort of perked my eyes was the R-CHOP plus X. So there are so many combinations being developed in the frontline setting of R-CHOP plus a ROR1 inhibitor, RCHOP plus a PI3 kinase. And having sat through that session, what I would simply tell you is the data look impeccable, that we are able to add drugs to R-CHOP, which may potentially change the efficacy and the frontline standard of care...
Yeah, so lots of interesting data has come out in diffuse large B-cell lymphoma. I would say a session that sort of perked my eyes was the R-CHOP plus X. So there are so many combinations being developed in the frontline setting of R-CHOP plus a ROR1 inhibitor, RCHOP plus a PI3 kinase. And having sat through that session, what I would simply tell you is the data look impeccable, that we are able to add drugs to R-CHOP, which may potentially change the efficacy and the frontline standard of care. All of these drugs are being now tested in a Phase III clinical trial. And this includes bispecific combinations with R-CHOP. So in a couple of years, we’re going to see the readout. But what I’ll say is that early Phase I/II data looks really promising. The other thing that I thought was interesting is the five year outcomes of the POLARIX data. And I think this is something that all oncologists want to look at is did polatuzumab continue to show benefits to patients if we give it as part of frontline treatment? And the short answer is yes. Even at five years, there was a persistent progression-free survival benefit. Less patients needed more lymphoma treatments if they got Pola-R-CHP and less patients died when they got Pola-R-CHP of lymphoma-related progressive disease. And so I’m highlighting a few things here. There’s lots of other stuff that happened at ASH 2024, but I think for those people treating DLBCL, some interesting things to keep an eye on.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Gilead-Kite, BMS-Juno, Miltenyi, Lilly Onclogy, Novartis, Seattle Genetics, Janssen, Abbvie, Cargo, Beigene, Galapagos, AstraZeneca: Consultancy, Honoraria; Miltenyi Biomedicine, Lilly Oncology: Research Funding; Tundra Therapeutics: Current holder of stock options in a privately-held company.
